Prasugrel Versus Placebo in Adult Sickle Cell Disease
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to assess the safety of Prasugrel in adult patients with sickle
cell disease (SCD) by monitoring the rate and severity of hemorrhagic events requiring
medical intervention compared to placebo for 30 days.